Message from the President
In written and oral testimony before the U.S. House of Representatives Oversight and Government Reform Committee today, former ISSCR president Sally Temple describes fetal tissue research as essential in studying and developing therapies for cancer, HIV, Zika, tuberculous, and other devastating diseases.Full story
- 13 December, 2018
- 26 November, 2018
ISSCR Comments on Reports of Chinese Scientists Performing Genome-Editing During Fertility TreatmentReports indicate that scientists in China have used CRISPR-mediated genome editing during in vitro fertilization to modify the genetic material of two embryos that were subsequently implanted into a patient, leading to the birth of two babies. As ISSCR and a number of other organizations have previously stated, the use of nuclear genome editing technologies, such as CRISPR, during fertility treatment is premature and should not be attempted at this time.Full story
Harvard University, U.S.
2018 ISSCR Year in Review
Stem cell science and regenerative medicine has made great progress in 2018, with significant clinical trials underway in several research areas, and advances in understanding that are illuminating new research pathways.
The role of the ISSCR in supporting the research and its responsible translation to the clinic has never been more important. I want to highlight for you some of ISSCR’s work throughout the year that I believe helps advance science, gives voice to our members, and sustains this ever-evolving field..
stem cell researchTake a closer look
Scientists Discover Bone-a fide Human Skeletal Stem Cell
If you’ve ever broken a bone, you are not alone. Statistics show that, over a lifetime, the average person experiences 2 bone fractures. For those with osteoporosis, that figure escalates, on average, to one bone fracture every 3 seconds, or nearly nine million fractures a year.
Recently, scientists have discovered a new cell type, human skeletal stem cells, that are providing insights into human skeletal development.
Stem Cells in the News
Media highlights in the field of stem cell research and its translation to the clinic.
4 December, Phys.org
29 November, Medical Xpress
28 November, ScienceDaily
A sampling of recent stem cell research commentaries, articles, and resources.
Featured Current Protocols in Stem Cell Biology Article
Highly Efficient CRISPR-Cas9-Mediated Genome Editing in Human Pluripotent Stem Cells, Maguire, et al (2018).Current Prot. Stem Cell Biology, e64. doi: 10.1002/cpsc.64.
T-type Calcium Channels Determine the Vulnerability of Dopaminergic Neurons to Mitochondrial Stress in Familial Parkinson Disease, Tabata, et al (2018), Stem Cell Reports.
- , Amsterdam
- , Los Angeles
Seeking a job? Have a job opening? the ISSCR Job Board gives members discounts on job postings here and in the monthly Pulse e-newsletter.
Other Stem Cell Events
Opportunities for researchers from around the world to explore the latest discoveries in stem cell science and regenerative medicine.
- , Nantes
Stem Cell CoursesView All
ISSCR and policy news from around the world.
13 December, Science
NIH Says Cancer Study Also Hit by Fetal Tissue Ban
10 December, Japan Times
China Gene-Editing Scientist's Project Rejected for WHO Database
4 December, The Irish Times
Italy's Vaccine-sceptic Party Sacks Board of Health Experts
Learn about ISSCR colleagues in the stem cell field from around the world.
Nils Pfaff, PhD
Feb 13, 2018
Hometown: Wilhelmshaven, Germany
Current residence: Düsseldorf, Germany
Graduate degree: PhD in Molecular Medicine from Hannover Medical School
Current position: Lab Head Preclinical Pharmacology, Bayer AG (Wuppertal, Germany)
What is the current focus of your research, and what do you find most rewarding about your work?
I am currently working in preclinical research in the Pharmaceuticals Division of Bayer. Apart from establishing iPSC-derived cells for target identification and validation, the main focus is in vivo pharmacology mostly in the therapeutic areas thrombosis and hemophilia. I really like the application-driven way of working in the (pharma) industry. It is great being involved in projects that always have the goal to improve the life of patients and being able to actually move these projects forward. It’s also fascinating to see how complex developing a new drug actually is and there is something new to learn every day.
What led you to become a scientist and to stem cell research?
I’ve always been interested in science. Back in high school I participated in a science club, which allowed me to work on smaller projects in a university lab during some of the vacations. At first I decided to study medicine but somehow realized I didn’t want to become a physician. That’s why I enrolled for Molecular Medicine (at Göttingen University, Germany), which turned out to be a great combination of science and medicine. When I started my PhD in 2008, iPS cells really were the hottest topic in biomedical research and the possibility to turn a skin cell into a stem cell into a blood/neuronal/cardiac cell was (and still is) just thrilling.
How do you spend your free time?
I regularly play football (soccer for the US folks…) and force myself to go running at least once a week. I also enjoy cooking (end eating, of course) a lot and have become a bit of a wine geek lately as well. Trying to stay in touch with friends and family is also very important for me.
What is something your peers would be surprised to learn about you?
I am a guitarist in a heavy metal band (the long hair is gone, though…) and regularly go to metal concerts and festivals.
What do you most value about your membership with the ISSCR?
Being member of the ISSCR is the best and easiest way to stay connected with the entire stem cell community and to permanently keep track of this still rapidly evolving field. Going to the annual meetings is always fun because you meet colleagues you haven’t seen for a whole year in most of the cases. Of course, the science presented is fascinating every time. Working in the ISSCR Industry Committee is a great way to discuss the industry’s perspective on translational aspects with the community – I think this dialogue is essential to bring effective stem cell-based therapies to patients.